help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maamra, M.
Right arrow Articles by Ross, R. J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maamra, M.
Right arrow Articles by Ross, R. J. M.
Endocrinology Vol. 142, No. 10 4389-4393
Copyright © 2001 by The Endocrine Society

ARTICLES

Generation of Human Soluble Leptin Receptor by Proteolytic Cleavage of Membrane-Anchored Receptors

M. Maamra, M. Bidlingmaier, M.-C. Postel-Vinay, Z. Wu, C. J. Strasburger and R. J. M. Ross

Division of Clinical Sciences (M.M., R.J.M.R.) Sheffield University, Sheffield S5 7AU, United Kingdom; Medizinische Klinik-Innenstadt (M.B., Z.W., C.J.S.), Muenchen 80336, Germany; and Institute National de la Santé et de la Recherche Médicale Unité 344 (M.-C.P.-V.), Endocrinologie Moleculaire, Faculte de Medecine Necker, Paris 75730 Cedex 15, France

Address all correspondence and requests for reprints to: Prof. R. J. M. Ross, Clinical Sciences, Northern General Hospital, Sheffield S5 7AU, United Kingdom. E-mail: r.j.ross{at}sheffield.ac.uk


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The leptin receptor (ObR) exists in multiple isoforms. In rodents, a soluble isoform is generated by alternative splicing; but in humans, there is no mRNA encoding soluble receptor (leptin binding protein). We investigated the hypothesis that human leptin binding protein can be generated by proteolytic cleavage of membrane-anchored leptin receptors (ObRb and ObRa). Leptin binding protein of similar size to that previously detected in human serum was detected by HPLC in medium of cells transfected with ObRa. ObRa exhibited higher expression at the cell surface than ObRb and generated greater levels of leptin binding protein. Ligand-mediated immunofunctional and immunofluorometric assays revealed that the leptin binding protein in medium bound both leptin and an ObR-specific antibody and that the level of leptin binding protein correlated with receptor expression at the cell surface. Phorbol 12-myristate-13-acetate and N-ethylmaleimide increased the accumulation of leptin binding protein, an indication that the production of leptin binding protein was up-regulated by PKC and sulfhydryl group activation. The protease inhibitors, TNF{alpha} protease inhibitor 1 and Immunex compound 2, could inhibit the production of leptin binding protein, indicating that the enzyme responsible for leptin binding protein cleavage belongs to the metalloprotease family. In conclusion, human leptin binding protein is generated by proteolytic cleavage of membrane-anchored leptin receptor by a metalloprotease.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
LEPTIN, THE PRODUCT of the Lep gene, is a hormone derived from adipocytes, and genetic deficiency results in extreme obesity. It is evident that leptin has multiple biological actions on feeding, metabolism, the neuroendocrine axis, and immune system (1). Leptin acts through a class 1 cytokine receptor (ObR), the product of a single gene, and mutations in this gene result in a similar phenotype to leptin deficiency (2). The leptin receptor is expressed in multiple isoforms. At least five splice variants of the leptin receptor have been detected in mice (3). In humans, at least four variants, which differ in the length of their cytoplasmic domains, have been reported (4). The predominant isoform is the short receptor (ObRa), which is expressed in most tissues, and at high level in the choroid plexus and brain microvessels (5, 6). In contrast, the full-length receptor (ObRb), although detectable by RT-PCR in many tissues, is only highly expressed in the hypothalamus (7), where expression exceeds that of the short form (8). ObRb is assumed to be responsible for transmitting the majority of biological signals mediating the central effects of leptin on appetite and energy expenditure, because deficient expression results in an obese diabetic phenotype (3). The function of the short form of the receptor, ObRa, has yet to be defined, although it has been suggested that it may act to transport leptin into the CSF (9).

A soluble receptor or leptin binding protein (LBP), circulating in complex with leptin, has been described in both the human and rodent. In humans, LBP can be precipitated by a leptin receptor antibody (10). In the pregnant mouse, LBP has been sequenced and confirmed as the extracellular domain of the leptin receptor (11). These results are consistent with observations made for other members of the class I cytokine family of receptors, a number of which produce soluble receptors that represent the extracellular domain of the receptor (12). The functional significance of soluble receptors is yet to be defined. They could act either as biomodulators of receptor signaling by competing for ligand binding or as transporters of cytokines in serum, reducing their degradation and clearance (13, 14). LBP is thought, in lean subjects, to play a role in restricting the availability of leptin to its hypothalamic receptor and thus inhibiting its effect on food intake and energy metabolism (10).

An mRNA encoding a putative soluble ObR has been detected in mice (3), but this has not been detected in humans (15). One of the most studied soluble cytokine receptors is the GH binding protein (GHBP). In rodents, alternative mRNA splicing at exon 8 encodes the soluble receptor. In contrast, human GHBP is generated by shedding of membraneanchored isoforms. This shedding is catalyzed by the metalloprotease A disintegrin and metalloprotease (ADAM) 17 (16) and has been shown to be enhanced upon PKC activation and sulfhydryl group alkylation (17). We have investigated the possibility that human LBP could be generated by shedding of the membraneanchored receptors, ObRa and ObRb.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Materials
The long form (ObRb) and short form (ObRa) leptin receptor cDNA in PCEP4 were a kind gift from A. Welcher (Amgen, Inc., Thousand Oaks, CA).

Recombinant human leptin was obtained from R&D systems (Abingdon, UK) and radiolabeled human leptin from Biogenesis (Poole, UK). N-ethylmaleimide (NEM) and phorbol 12-myristate-13 acetate (PMA) were purchased from Sigma-Aldrich Corp. (Poole, UK). We used two hydroxyamid acid-based inhibitors, TNF{alpha} protease inhibitor 1 (TAPI-1) and modified metalloprotease inhibitor Immunex compound 2 (IC2; Immunex Corp., Seattle, WA), which are general inhibitors of mammalians shedding metalloproteases (18, 19). The small TAPI-1 inhibitor was purchased from Peptides International, Inc. (Louisville, KY). The calcium phosphate transfection kit and tissue culture solutions were purchased from Gibco Ltd. (Paisley, UK).

Cell culture
293 cells (human kidney embryonal cell line) were grown in DMEM Nut F12 medium supplemented with 10% FCS, 100 IU and 100 µg/ml penicillin/streptomycin, and 2 nM L-glutamine. Cells were plated 24 h before transfection.

Binding studies
For cell surface binding, 293 cells were transiently transfected with leptin receptor cDNA using the calcium phosphate method. The cells were incubated in serum free medium for 16 h, and the medium was then collected for soluble binding protein measurement. Cells were then washed in PBS containing 1% BSA and incubated with I125-labeled leptin (50,000 cpm/ml) for 3 h at room temperature in the presence or absence of an excess of cold leptin (3 µg/ml). Cells were subsequently washed in PBS and solubilized in 1 N NaOH for counting radiation.

HPLC assay
LBP was assayed in culture media using gel filtration. The medium from ObRa-transfected cells was concentrated 10 times by freeze drying and incubated overnight at 4 C with 105 cpm I125 leptin in PBS-0.1% BSA. A parallel incubation was carried out in the presence of an excess of cold leptin. The samples were then analyzed by gel filtration, using a liquid chromatograph (Waters Corp., Milford, MA) equipped with a sample injector (model U6K) fitted with a 250-µl loop and an analytic HPLC Protein Pak 300 SW (Waters Corp.; 0.75 x 30 cm). Elution was performed automatically using a degassed buffer (0.1 M Na2SO4, 0.1 M K2HPO4, pH 7), pumped at a rate of 0.5 ml/min. Radioactivity was recorded on line using a Berthold LB2040 {gamma}-detector (Berthold, Elancourt, France) connected to a Compaq computer.

Soluble LBP assays [ligand-mediated immunofunctional assays (LIFA) and immunofluorometric assays (IFMA)]
Medium of 293 transfected with the leptin receptors was collected after overnight incubation and concentrated 25-fold using the Centripep YM10 devices (Millipore Corp. UK Ltd., Watford, UK). Biologically active soluble leptin binding protein (LBP) was measured by LIFA and IFMA (20), and cell surface binding was performed on the same cells. In brief, LIFA involves capture of LBP from samples by an anti-LBP monoclonal antibody immobilized on microtiter plates, saturation of all leptin binding sites of the bound LBP by recombinant leptin, and detection of bound leptin by a monoclonal antileptin antibody. Both the anti-LBP and the antileptin monoclonal antibodies bind to an epitope distant from the hormone-receptor interaction site. The LIFA is expected to reflect the biologically active LBP, because only those molecules that bind leptin are translated into a signal. In the sandwich-type assay (IFMA), the protein was captured by the same anti-LBP antibody as in the LIFA; but for detection, another labeled antibody against the extracellular domain of the receptor was used. In both LIFA and IFMA, concentrated serum-free medium was used as a matrix of the assay, and recombinant human leptin receptor ectodomain was used as a standard.

Effect of NEM and PMA on LBP production
ObR-transfected cells were incubated at 37 C in serum-free medium supplemented with 5 nM NEM, 1 µg/ml PMA, or vehicle dimethylsulfoxide (DMSO) for 90 min. The media were concentrated and analyzed by LIFA.

For the metalloprotease experiments, cells were preincubated for 15 min with 30 µM metalloprotease inhibitor TAPI1 or 45 µM of IC2, or vehicle, before treatment with DMSO, PMA, or NEM. The media was then concentrated and analyzed by LIFA.

Statistics
For analysis of binding data and LIFA, ANOVA with post hoc Bonferroni analysis was used, and the level of significance was accepted as P < 0.05. LIFA and IFMA results were compared by regression analysis.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Binding studies
We compared binding of iodinated leptin at the cell surface of cells transfected with ObRa, ObRb, or control salmon sperm DNA. Transient transfection studies were performed in 293 cells. Transfection of the leptin receptor lead to significant binding activity of leptin to the cells and cells transfected with ObRa showed significantly greater binding of iodinated leptin compared with cells expressing ObRb, P < 0.01 (Fig. 1AGo). In simultaneous experiments studying signaling, ObRa and ObRb were cotransfected with a ß-galactosidase expression vector. In these experiments, transfection efficiency for ObRa and ObRb were equivalent (data not shown).



View larger version (13K):
[in this window]
[in a new window]
  		Figure 1. Percentage specific binding of iodinated leptin to 293 cells in monolayer transiently transfected with leptin receptor and LBP concentration in the medium. A, 293 cells transiently transfected with ObRa, ObRb, or control salmon sperm were incubated overnight in starvation medium, which was then removed before addition of 125I-leptin plus or minus an excess of cold leptin. The results of cell monolayer binding are expressed as percentage specific binding. B, The media from the same cells (overnight incubation) were concentrated, and the LBP concentration (ng/ml) was measured by LIFA. *, P < 0.01, ObRa vs. ObRb.

 
LBP
We investigated whether a LBP could be generated from membrane-anchored receptor. Medium from 293 cells transiently transfected with ObRa, ObRb, or control salmon sperm was concentrated. LBP was measured by HPLC, LIFA, and IFMA. HPLC on concentrated medium from cells transfected with ObRa revealed 9.0% specific binding of iodinated leptin with an elution time similar to the leptin binding activity we have previously reported in normal human serum (21) (Fig. 2Go). The results for the LIFA assays are given in Fig. 1BGo. LBP was detectable in concentrated medium from cells transfected with ObRb and ObRa. The level of LBP correlated with specific binding of leptin on the cell surface (r = 0.80, P < 0.05), and the LIFA and IFMA levels correlated (r = 0.96, P < 0.001), confirming the molecular identity between the leptin binding activity detected in the medium and the soluble leptin receptor (Fig. 3Go).



View larger version (14K):
[in this window]
[in a new window]
  		Figure 2. Elution profile of 125I leptin incubated with concentrated culture medium of 293 cells transfected with ObRa. Medium from ObRa-transfected cells was concentrated, and incubation was performed with 125I leptin plus (thin line) or minus (thick line) an excess cold leptin, and the samples were analyzed by HPLC gel filtration column. The chromatograph shows a specific peak for LBP with 9% binding of tracer.

 


View larger version (11K):
[in this window]
[in a new window]
  		Figure 3. Comparison of LBP concentration by LIFA and IFMA. To determine whether all the extracellular domain of the leptin receptor present in the medium is able to bind leptin, several samples were analyzed by IFMA (uses antibody specific to the receptor) and in parallel by LIFA (uses ligand, leptin). IFMA concentrations of LBP were plotted against the corresponding LIFA measurement, and this confirmed a close correlation between the two assays (r = 0.96, P < 0.001).

 
Effect of PMA and NEM on LBP production
We investigated whether PMA and NEM could regulate LBP production. For these experiments, medium from 293 cells transfected with the ObRa leptin receptor was collected after 90 min incubation with PMA, NEM, or vehicle (DMSO). The phorbol ester PMA was used to activate PKC, and NEM was used for alkylation of sulfhydryl groups. Both PMA and NEM promoted the appearance of soluble receptor in the medium of cells transfected with membrane-anchored receptors (Fig. 4Go). In DMSO-only treated cells, the levels of LBP detected was very low because of the short incubation period. PMA treatment significantly increased the levels of LBP in ObRa-transfected cells by about 2-fold (2.16 ± 0.38, mean ± SEM fold induction) and NEM by about 30-fold (31.36 ± 4.12, mean ± SEM fold induction).



View larger version (12K):
[in this window]
[in a new window]
  		Figure 4. Effect of NEM and PMA on LBP production. A total of 293 cells transfected with leptin receptor (ObRa) were incubated for 90 min (not overnight as in Fig. 1BGo) in serum-free medium supplemented with DMSO (vehicle), 1 µg/ml PMA, or 5 nM NEM. The media were concentrated, and LBP was measured by LIFA and IFMA.

 
Effect of metalloprotease inhibitors on basal and enhanced LBP production
We investigated whether two metalloproteases inhibitors, IC2 and the small TAPI1 inhibitor could inhibit basal, PMA-, or NEM-induced LBP production (Fig. 5Go). For these experiments, cells transfected with ObRa were preincubated for 15 min with the metalloprotease inhibitors or vehicle (DMSO), before the incubation with PMA, NEM, or vehicle. The LBP levels in the conditioned media were assayed by LIFA. The basal levels of LBP were low because of the short period of incubation. Preincubation with the metalloprotease inhibitors IC2 or TAPI1 inhibited LBP production in the conditioned medium induced by PMA and NEM.



View larger version (24K):
[in this window]
[in a new window]
  		Figure 5. Effect of a metalloprotease inhibitor on PMA- and NEM-induced LBP production. 293 cells transfected with ObRa were treated in serum-free medium for 15 min with metalloprotease inhibitors (IC2 or TAPI1) before adding PMA (1 µg/ml) or NEM (5 mM) or vehicle (DMSO) for 90 min. The medium was then collected and concentrated, and LBP was measured by LIFA.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
We have demonstrated that generation of the human LBP may occur by proteolytic cleavage of membrane-bound leptin receptor. Expression of the membrane-anchored receptor isoforms in 293 cells resulted in the appearance in the medium of LBP, as assessed by HPLC. Thus, cells could release, in the medium, a molecule bioactive for the binding of leptin. The detected LBP was similar to that we have previously reported for leptin binding activity in human serum (21). The nature of the ligand binding activity was further characterized by 2 separate immunoassays, which gave similar results. The IFMA (antibody recognition of LBP) and the LIFA (measurement of leptin binding) assays confirmed that the leptin binding activity that we detected in the cells corresponds to the extracellular domain of the leptin receptor. Experiments using inhibitors demonstrated that cleavage of LBP was through a metalloprotease.

The leptin receptor is homologous to the cytokine receptor family. A feature of cytokine receptors, including GH and IL-6 receptors, is the production of soluble receptor, which circulates as binding protein. Two distinct mechanisms for soluble receptor production, not mutually exclusive, have been described. The soluble IL-6 and IL-1 receptors may be generated both by proteolytic cleavage and alternative splicing (22, 23, 24). Similarly, the soluble GH receptor (GHR) is generated by alternative splicing in rodents (25), proteolysis in humans (17), and both mechanisms in the monkey (26). In rodent tissues, a splice variant encoding LBP has been characterized (3), but this does not occur in the human, where the gene lacks a polyadenylation signal in the potential 3' terminal exon (15). Our findings do not exclude the possibility that an uncharacterized alternative spliced mRNA could contribute to the pool of human LBP in vivo, but our results do demonstrate that human LBP may be generated by shedding of both the long and short forms of the leptin receptor, and that LBP levels are related to receptor expression. Changes in levels of LBP could reflect changes in expression of ObR receptor, as seen with the GHR (27). Previously, Liu et al. (28) reported that no soluble receptor could be detected by radioligand binding and immunoprecipitation in the medium of COS7 cells transfected with ObRb. However, in our system, we could detect LBP in the medium 293 cells transfected with ObRb by LIFA and IFMA. The difference is likely to be attributable to the higher sensitivity of the IFMA and LIFA. ObRa consistently shows a higher level of expression at the cell surface, as previously reported. This is not related to a difference in affinity for leptin (29). We now show that ObRa also generates more LBP. The level of LBP detected in the medium from cells expressing the ObR was closely related to the level of expression of the receptor at the cell surface. This suggests that the availability of membrane receptor may, in part, determine the production of LBP. Because ObRa is expressed at a higher level than ObRb and is the predominant receptor isoform in peripheral tissues, it is likely that ObRa makes a significant contribution to circulating LBP. The soluble receptor has been shown, in vitro, to be able to compete for binding of leptin to ObRb (28). Thus, the differential expression of the leptin receptor isoforms ObRa and ObRb may determine the level of circulating LBP and the signaling profile activated in individual cells.

LBP has been measured in physiological and clinical situations. Circulating levels of LBP are low at birth, high in the prepubertal years, then fall (through puberty) to remain stable during adult life (21). LBP levels are lower in obese patients, compared with lean (30), whereas leptin levels are higher in the obese, suggesting that obese individuals are resistant to free leptin. In adults, transport of free leptin into the CSF seems to be saturated at low concentrations of serum free leptin, whereas bound leptin increases in parallel to serum concentrations over the whole physiological ranges (31), and the ratio of leptin in cerebrospinal fluid to serum fluid is decreased in obesity (32). Bound leptin levels are higher in pregnant women during the third semester of pregnancy, whereas free leptin levels are similar (33). It has been suggested that bound leptin may regulate maternal metabolism in the pregnant woman. Thus, LBP may act to carry leptin as well as modulate metabolism.

Several cell surface receptors have been shown to undergo proteolytic cleavage (12). The protease involved in the cleavage of TNF has been identified and belongs to the ADAM (a disintegrin and metalloprotease) family (34). For most cytokine receptors, the enzyme responsible for proteolysis has not yet been identified, but metalloprotease inhibitors have been shown to inhibit shedding of many receptors. The mechanism for proteolytic cleavage of GHR, another cytokine receptor, have now been well characterized. GHR shedding can be promoted by PKC activation and sulfhydryl alkylation and be inhibited by the metalloprotease inhibitor IC3 (17). Shedding of TNF and IL6 soluble receptors have also been shown to be promoted by PMA. In our experiments, PMA induced a 2-fold increase in LBP, similar to that reported for GHBP (35), suggesting that PKC could activate shedding. The sulhydryl alkylating agent NEM led to an even-higher increase in LBP, again similar to that observed with GHBP (17). The metalloprotease ADAM17 is an enzyme required for PMA-induced GHBP shedding (16). So, our findings raised the possibility that human LBP could, in vivo, be generated by shedding that involves a metalloprotease of the same family. We confirmed this by demonstrating that LBP production could be inhibited by the use of two metalloprotease inhibitors, IC2 and TAPI1.

Cleavage of cytokine receptors by shedding is largely accepted as a mechanism for the production of soluble receptor; however, the precise location of the event is not yet established. It is not clear whether proteolysis occurs intracellularly, at the cell surface or after internalization. There is good evidence for the TNF receptor, that shedding occurs intracellularly (36). For the GHR, it seems that proteolysis occurs before internalization, as a truncated receptor that fails to internalize generates high levels of GHBP (37). NEM is an internalization inhibitor (38), and incubation of leptin receptor-expressing cells with NEM resulted in high levels of LBP, suggesting that shedding of the leptin receptor occurs at the membrane. We do not exclude a specific effect of NEM on the leptin receptor shedding, because at least one free cysteine in the extracellular domain of ObR can be alkylated by NEM (39).

In summary, we have shown that cell surface human leptin receptor can be shed by a metalloprotease to produce LBP and that ObRa generates a larger proportion of LBP than ObRb. This shedding most likely occurs at the cell surface and is activated by PKC. A possible role for the short receptor isoform, ObRa, could be to provide soluble receptor to act as carrier of leptin from its peripheral site of production to its central site of neuroactions.


   Footnotes
 
We are grateful for support from Serono Laboratories, Inc. M. Maamra is supported by a Ph.D. studentship from the Society for Endocrinology.

Abbreviations: ADAM, A disintegrin and metalloprotease; DMSO, dimethylsulfoxide; GHBP, GH binding protein; GHR, GH receptor; IC2, Immunex compound 2; IFMA, immunofluorometric assays; LBP, leptin binding protein; LIFA, ligand-mediated immunofunctional assays; NEM, N-ethylmaleimide; PMA, phorbol 12-myristate-13-acetate; TAPI-1, TNF{alpha} protease inhibitor 1.

Received April 13, 2001.

Accepted for publication June 27, 2001.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Houseknecht KL, Baile CA, Matteri RL, Spurlock ME 1998 The biology of leptin: a review. J Anim Sci 76:1405–1420[Abstract/Free Full Text]
  2. Tartaglia LA 1997 The leptin receptor. J Biol Chem 272:6093–6096[Free Full Text]
  3. Lee GH, Proenca R, Montez JM, et al. 1996 Abnormal splicing of the leptin receptor in diabetic mice. Nature 379:632–635[CrossRef][Medline]
  4. Kielar D, Clark JS, Ciechanowicz A, Kurzawski G, Sulikowski T, Naruszewicz M 1998 Leptin receptor isoforms expressed in human adipose tissue. Metabolism 47:844–847[CrossRef][Medline]
  5. Bjorbaek C, Elmquist JK, Michl P, et al. 1998 Expression of leptin receptor isoforms in rat brain microvessels. Endocrinology 139:3485–3491[Abstract/Free Full Text]
  6. Tartaglia LA, Dembski M, Weng X, et al. 1995 Identification and expression cloning of a leptin receptor, OB-R. Cell 83:1263–1271[CrossRef][Medline]
  7. Mercer JG, Hoggard N, Williams LM, Lawrence CB, Hannah LT, Trayhurn P 1996 Localization of leptin receptor mRNA and the long form splice variant (Ob-Rb) in mouse hypothalamus and adjacent brain regions by in situ hybridization. FEBS Lett 387:113–116[CrossRef][Medline]
  8. Ghilardi N, Ziegler S, Wiestner A, Stoffel R, Heim MH, Skoda RC 1996 Defective STAT signaling by the leptin receptor in diabetic mice. Proc Natl Acad Sci USA 93:6231–6235[Abstract/Free Full Text]
  9. Kastin AJ, Pan W, Maness LM, Koletsky RJ, Ernsberger P 1999 Decreased transport of leptin across the blood-brain barrier in rats lacking the short form of the leptin receptor. Peptides 20:1449–1453[CrossRef][Medline]
  10. Sinha MK, Opentanova I, Ohannesian JP, et al. 1996 Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting. J Clin Invest 98:1277–1282[Medline]
  11. Gavrilova O, Barr V, Marcus-Samuels B, Reitman M 1997 Hyperleptinemia of pregnancy associated with the appearance of a circulating form of the leptin receptor. J Biol Chem 272:30546–30551[Abstract/Free Full Text]
  12. Muller-Newen G, Kohne C, Heinrich PC 1996 Soluble receptors for cytokines and growth factors. Int Arch Allergy Immunol 111:99–106[Medline]
  13. Huang L, Wang Z, Li C 2000 Modulation of circulating leptin levels by its soluble receptor. J Biol Chem 276:6343–6349[Abstract/Free Full Text]
  14. Peters M, Jacobs S, Ehlers M, et al. 1996 The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med 183:1399–1406[Abstract/Free Full Text]
  15. Chua SC, Koutras IK, Han L, et al. 1997 Fine structure of the murine leptin receptor gene: splice site suppression is required to form two alternatively spliced transcripts. Genomics 45:264–270[CrossRef][Medline]
  16. Zhang Y, Jiang J, Black RA, Baumann G, Frank SJ 2000 Tumor necrosis factor-alpha converting enzyme (TACE) is a growth hormone binding protein (GHBP) sheddase: the metalloprotease TACE/ADAM-17 is critical for (PMA-induced) GH receptor proteolysis and GHBP generation. Endocrinology 141:4342–4348[Abstract/Free Full Text]
  17. Alele J, Jiang J, Goldsmith JF, et al. 1998 Blockade of growth hormone receptor shedding by a metalloprotease inhibitor. Endocrinology 139:1927–1935[Abstract/Free Full Text]
  18. Mohler KM, Sleath PR, Fitzner JN, et al. 1994 Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 370:218–220[CrossRef][Medline]
  19. Feehan C, Darlak K, Kahn J, Walcheck B, Spatola AF, Kishimoto TK 1996 Shedding of the lymphocyte L-selectin adhesion molecule is inhibited by a hydroxamic acid-based protease inhibitor. Identification with an L-selectin-alkaline phosphatase reporter. J Biol Chem 271:7019–7024[Abstract/Free Full Text]
  20. Wu Z, Bidlingmaier M, Bennett WF, Morrison KM, Strasburger CJ Interference-free measurement of human growth hormone binding protein (hGHBP) levels in the presence of high concentrations of a hGH analogue. Proc 82nd Annual Meeting of The Endocrine Society, Toronto, Canada, 2000, p 492 (Abstract)
  21. Quinton ND, Smith RF, Clayton PE, et al. 1999 Leptin binding activity changes with age: the link between leptin and puberty. J Clin Endocrinol Metab 84:2336–2341[Abstract/Free Full Text]
  22. Muller-Newen G, Kohne C, Keul R, et al. 1996 Purification and characterization of the soluble interleukin-6 receptor from human plasma and identification of an isoform generated through alternative splicing. Eur J Biochem 236:837–842[Medline]
  23. Mullberg J, Schooltink H, Stoyan T, et al. 1993 The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol 23:473–480[Medline]
  24. Liu C, Hart RP, Liu XJ, Clevenger W, Maki RA, De Souza EB 1996 Cloning and characterization of an alternatively processed human type II interleukin-1 receptor mRNA. J Biol Chem 271:20965–20972[Abstract/Free Full Text]
  25. Tiong TS, Herington AC 1991 Identification of a novel growth hormone binding protein mRNA in rat liver. Biochem Biophys Res Commun 180:489–495[CrossRef][Medline]
  26. Martini JF, Pezet A, Guezennec CY, Edery M, Postel-Vinay MC, Kelly PA 1997 Monkey growth hormone (GH) receptor gene expression. Evidence for two mechanisms for the generation of the GH binding protein. J Biol Chem 272:18951–18958[Abstract/Free Full Text]
  27. Baumann G 1995 Growth hormone binding protein-errant receptor or active player? Endocrinology 136:377–378[CrossRef][Medline]
  28. Liu C, Liu XJ, Barry G, Ling N, Maki RA, De Souza EB 1997 Expression and characterization of a putative high affinity human soluble leptin receptor. Endocrinology 138:3548–3554[Abstract/Free Full Text]
  29. Barr VA, Lane K, Taylor SI 1999 Subcellular localization and internalization of the four human leptin receptor isoforms. J Biol Chem 274:21416–21424[Abstract/Free Full Text]
  30. Diamond FBJ, Eichler DC, Duckett G, Jorgensen EV, Shulman D, Root AW 1997 Demonstration of a leptin binding factor in human serum. Biochem Biophys Res Commun 233:818–822[CrossRef][Medline]
  31. Brabant G, Horn R, von zur MA, et al. 2000 Free and protein bound leptin are distinct and independently controlled factors in energy regulation. Diabetologia 43:438–442[CrossRef][Medline]
  32. Schwartz MW, Peskind E, Raskind M, Boyko EJ, Porte DJ 1996 Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat Med 2:589–593[CrossRef][Medline]
  33. Widjaja A, Hofmann R, Bruhn J, von zur MA, Brabant G 2000 Free and bound leptin levels during human pregnancy. Gynecol Endocrinol 14:264–269[Medline]
  34. Black RA, Rauch CT, Kozlosky CJ, et al. 1997 A metalloproteinase disintegrin that releases tumour-necrosis factor-{alpha} from cells. Nature 385:729–733[CrossRef][Medline]
  35. Harrison SM, Barnard R, Ho KY, Rajkovic I, Waters MJ 1995 Control of growth hormone (GH) binding protein release from human hepatoma cells expressing full-length GH receptor. Endocrinology 136:651–659[Abstract]
  36. Choi SS, Gatanaga M, Granger GA, Gatanaga T 1996 Prostaglandin-E2 regulation of tumor necrosis factor receptor release in human monocytic THP-1 cells. Cell Immunol 170:178–184[CrossRef][Medline]
  37. Ross RJ, Esposito N, Shen XY, et al. 1997 A short isoform of the human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein. Mol Endocrinol 11:265–273[Abstract/Free Full Text]
  38. Timar J, Bradley N, Robertson D, Davies AJ 1986 Induction of ligand carrying/natural liposomes in cancer cells. Acta Morphol Hung 34:299–310[Medline]
  39. Haniu M, Arakawa T, Bures EJ, et al. 1998 Human leptin receptor. Determination of disulfide structure and N-glycosylation sites of the extracellular domain. J Biol Chem 273:28691–28699[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
S. E. Cohen, E. Kokkotou, S. B. Biddinger, T. Kondo, R. Gebhardt, J. Kratzsch, C. S. Mantzoros, and C. R. Kahn
High Circulating Leptin Receptors with Normal Leptin Sensitivity in Liver-specific Insulin Receptor Knock-out (LIRKO) Mice
J. Biol. Chem., August 10, 2007; 282(32): 23672 - 23678.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
C. A. Ducsay, K. Hyatt, M. Mlynarczyk, K. M. Kaushal, and D. A. Myers
Long-term hypoxia increases leptin receptors and plasma leptin concentrations in the late-gestation ovine fetus
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2006; 291(5): R1406 - R1413.
[Abstract] [Full Text] [PDF]

Home page
 J ANIM SCIHome page
S. K. Jacobi, N. K. Gabler, K. M. Ajuwon, J. E. Davis, and M. E. Spurlock
Adipocytes, myofibers, and cytokine biology: New horizons in the regulation of growth and body composition
J Anim Sci, April 1, 2006; 84(13_suppl): E140 - E.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. Stein, E. Vasquez-Garibay, J. Kratzsch, E. Romero-Velarde, and G. Jahreis
Influence of Nutritional Recovery on the Leptin Axis in Severely Malnourished Children
J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 1021 - 1026.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
M. C. Henson and V. D. Castracane
Leptin in Pregnancy: An Update
Biol Reprod, February 1, 2006; 74(2): 218 - 229.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
N. Gallardo, C. Arribas, M. Villar, M. Ros, J. M. Carrascosa, C. Martinez, and A. Andres
ObRa and ObRe Are Differentially Expressed in Adipose Tissue in Aged Food-Restricted Rats: Effects on Circulating Soluble Leptin Receptor Levels
Endocrinology, November 1, 2005; 146(11): 4934 - 4942.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Kratzsch, C. Schubring, B. Stitzel, A. Bottner, A. Berthold, J. Thiery, and W. Kiess
Inverse Changes in the Serum Levels of the Soluble Leptin Receptor and Leptin in Neonates: Relations to Anthropometric Data
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2212 - 2217.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Cohen, G. Yang, X. Yu, A. A. Soukas, C. S. Wolfish, J. M. Friedman, and C. Li
Induction of Leptin Receptor Expression in the Liver by Leptin and Food Deprivation
J. Biol. Chem., March 18, 2005; 280(11): 10034 - 10039.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
J. T Smith, P. J Mark, and B. J Waddell
Developmental increases in plasma leptin binding activity and tissue Ob-Re mRNA expression in the rat
J. Endocrinol., March 1, 2005; 184(3): 535 - 541.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
D. E. Edwards, R. P. Bohm Jr, J. Purcell, M. S. Ratterree, K. F. Swan, V. D. Castracane, and M. C. Henson
Two Isoforms of the Leptin Receptor Are Enhanced in Pregnancy-Specific Tissues and Soluble Leptin Receptor Is Enhanced in Maternal Serum with Advancing Gestation in the Baboon
Biol Reprod, November 1, 2004; 71(5): 1746 - 1752.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Belouzard, D. Delcroix, and Y. Rouille
Low Levels of Expression of Leptin Receptor at the Cell Surface Result from Constitutive Endocytosis and Intracellular Retention in the Biosynthetic Pathway
J. Biol. Chem., July 2, 2004; 279(27): 28499 - 28508.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
G. Yang, H. Ge, A. Boucher, X. Yu, and C. Li
Modulation of Direct Leptin Signaling by Soluble Leptin Receptor
Mol. Endocrinol., June 1, 2004; 18(6): 1354 - 1362.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Zarkesh-Esfahani, A. G. Pockley, Z. Wu, P. G. Hellewell, A. P. Weetman, and R. J. M. Ross
Leptin Indirectly Activates Human Neutrophils via Induction of TNF-{alpha}
J. Immunol., February 1, 2004; 172(3): 1809 - 1814.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Schroth, J. Kratzsch, M. Groschl, M. Rauh, W. Rascher, and J. Dotsch
Increased Soluble Leptin Receptor in Children with Nephrotic Syndrome
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5497 - 5501.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
N. Kado, J. Kitawaki, H. Koshiba, H. Ishihara, Y. Kitaoka, M. Teramoto, and H. Honjo
Relationships between the serum levels of soluble leptin receptor and free and bound leptin in non-pregnant women of reproductive age and women undergoing controlled ovarian hyperstimulation
Hum. Reprod., April 1, 2003; 18(4): 715 - 720.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Ge, L. Huang, T. Pourbahrami, and C. Li
Generation of Soluble Leptin Receptor by Ectodomain Shedding of Membrane-spanning Receptors in Vitro and in Vivo
J. Biol. Chem., November 22, 2002; 277(48): 45898 - 45903.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Sandowski, N. Raver, E. E. Gussakovsky, S. Shochat, O. Dym, O. Livnah, M. Rubinstein, R. Krishna, and A. Gertler
Subcloning, Expression, Purification, and Characterization of Recombinant Human Leptin-binding Domain
J. Biol. Chem., November 22, 2002; 277(48): 46304 - 46309.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Kratzsch, A. Lammert, A. Bottner, B. Seidel, G. Mueller, J. Thiery, J. Hebebrand, and W. Kiess
Circulating Soluble Leptin Receptor and Free Leptin Index during Childhood, Puberty, and Adolescence
J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4587 - 4594.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
N. Lahlou, T. Issad, Y. Lebouc, J.-C. Carel, L. Camoin, M. Roger, and J. Girard
Mutations in the Human Leptin and Leptin Receptor Genes as Models of Serum Leptin Receptor Regulation
Diabetes, June 1, 2002; 51(6): 1980 - 1985.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. M. H. van Dielen, C. van 't Veer, W. A. Buurman, and J. W. M. Greve
Leptin and Soluble Leptin Receptor Levels in Obese and Weight-Losing Individuals
J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1708 - 1716.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maamra, M.
Right arrow Articles by Ross, R. J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maamra, M.
Right arrow Articles by Ross, R. J. M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals